| Drug | Use Frequency (n/%) | Dosage Arithmetic (mean/median mg) | Usage Time (years) Mean/median/maximum |
| Synthetic DMARDs | 150 |
|
|
| Methotrexate | 75 (70) | 18.13/20 | 10/8/37 |
| Leflunomide | 49 (45.8) | 20/20 | 6.7/5/18 |
| Hydroxychloroquine | 9 (8.4) | 400/400 | 6/4.5/15 |
| Chloroquine | 8 (7.47) | 234.37/250 | 16.5/11.5/33 |
| Sulfasalazine | 8 (7.47) | 1500/100 | 4.5/3/13 |
| Cyclosporine | 1 (0.9) | 100/100 | 10/10/10 |
| Biologic DMARDs | 20 |
|
|
| Adalimumab | 4 (3.73) | 40/40 | 5.5/6/7 |
| Infliximab | 4 (3.73) | 3.62/3.75 | 6.5/6/10 |
| Tocilizumab | 3 (2.8) | 8/8 | 3.6/4/5 |
| Abatacept | 2 (1.86) | 750/750 | 3/3/3 |
| Golimumab | 2 (1.86) | 50/50 | 3/3/3 |
| Certolizumab | 2 (1.86) | 400/400 | 4/4/4 |
| Etanercept | 1 (0.9) | 50/50 | 4/4/4 |
| Tofacitinib | 2 (1.86) | 5/5 | 3/3/3 |
| Main Treatment Schemes | |||
| Anti-Rheumatic drugs | Frequency of use n (%) | ||
| Methotrexate monotherapy | 29 (27.1) | ||
| Leflunomide monotherapy | 11 (10.28) | ||
| Methotrexate + leflunomide | 23 (21.49) | ||
| Leflunomide + infliximab | 3 (2.8) | ||
| Methotrexate + hydroxychloroquine | 3 (2.8) | ||
| Methotrexate + cloroquine | 3 (2.8) | ||
| Methotrexate + leflunomide + chloroquine | 3 (2.8) | ||
| Hydroxychloroquine monotherapy | 3 (2.8) | ||
| Methotrexate + adalimumab | 3 (2.8) | ||
| Methotrexate + sulfasalazine | 1 (0.9) | ||